Targeted Therapies for Breast Cancer Treatment in the UK
Targeted therapies represent an important advancement in breast cancer treatment in the UK. Unlike chemotherapy, which affects rapidly dividing cells throughout the body, targeted therapies are designed to interfere with specific molecules or pathways that cancer cells rely on for growth and survival. This precision allows for more focused treatment while limiting damage to healthy cells.
One of the most established targeted treatments in breast cancer care is therapy directed at the HER2 protein. HER2-positive breast cancers produce excess amounts of this protein, which promotes aggressive tumour growth. Targeted medicines block HER2 signals, slowing or stopping cancer progression. These therapies are commonly used alongside chemotherapy, particularly in early-stage and advanced disease.
Targeted therapies may be given before surgery to shrink tumours or after surgery to reduce the risk of recurrence. In advanced breast cancer, they can help control disease spread and relieve symptoms. Treatment plans are tailored based on tumour biology and patient health.
Side effects of targeted therapies differ from those of chemotherapy. Patients may experience fatigue, diarrhoea, skin changes, or effects on heart function, depending on the medication used. Regular monitoring, including heart scans and blood tests, ensures treatment safety.
In the UK, patients receiving targeted therapy are closely supported by oncology teams and breast care nurses. Education is provided on recognising side effects and maintaining wellbeing during treatment.
Targeted therapies have improved outcomes for many people with breast cancer and continue to be an important component of personalised treatment strategies within UK healthcare.